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ABSTRACT
Glioblastoma multiforme (GBM) is characterized by a strong self-renewal 
potential and a poor differentiation state. Since receptor-like tyrosine kinase (RYK) 
activates the WNT/β-catenin pathway essential for cancer stem cell maintenance, 
we evaluated its contribution in conferring stemness to GBM cells. Here, we report 
that Ryk (related-to-receptor tyrosine kinase), an atypical tyrosine kinase receptor, 
is upregulated in samples from GBM patients as well as in GSCs. Ryk overexpression 
confers stemness properties to GBM cells through the modulation of the canonical Wnt 
signaling and by promoting the activation of pluripotency-related transcription factor 
circuitry and neurosphere formation ability. In contrast, siRNA-mediated knockdown 
of Ryk expression suppresses this stem-like phenotype. Rescue experiments reveal 
that stemness-promoting activity of Ryk is attributable, at least in part, to β-catenin 
stabilization. Furthermore, Ryk overexpression improves cell motility and anchorage 
independent cell growth. Taken together, our findings demonstrate that Ryk 
promotes stem cell-like and tumorigenic features to glioma cells its essential for the 
maintenance of GSCs and could be a target of novel therapies.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most 
common and aggressive primary brain tumor and 
one of the most devastating human malignancies. 
Recent studies have suggested that this tumor 
arises from a small population of cancer stem cells 
(CSCs, or tumor-initiating cells). CSCs retain many 
properties of normal neural stem cells (NSCs), 
such as self-renewal and multipotency [1, 2]. 
They are believed to constitute the tumor’s driving 
force and to be responsible for tumor recurrence and 
radio- and chemo-resistance [3–6]. Indeed, blocking 
self-renewal signaling by targeting surface markers 
or forcing differentiation of GBM CSCs (GSCs) may 
represent potential effective therapeutic strategies for 
GBM. However, poor understanding of the molecular 
pathways involved in CSCs expansion and maintenance 
has hindered the development of such approaches.
The WNT/β-catenin signaling pathway is essential in 
regulating self-renewal and proliferation or differentiation 
of NSCs and CSCs. After binding cell-surface receptors, 
WNT initiates a transduction cascade that stabilizes the 
transcriptional co-activator β-catenin, allowing it to 
translocate to the nucleus, form a transcriptional activation 
complex with TCF/LEFT (T-cell specific transcription 
factor/lymphoid enhancer-binding factor), and initiate 
transcription of targeted genes [7]. Deregulation of WNT 
signaling in NSCs or progenitor cells due to genetic or 
epigenetic alterations can promote CSCs survival [8]. On 
the other hand, persistent β-catenin activation has also 
been demonstrated in GSCs, promoting self-renewal, 
invasiveness, neurosphere formation, and epithelial-to-
mesenchymal transition (EMT) [9, 10].
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Receptor-like tyrosine kinase, or related-to-receptor 
tyrosine kinase (RYK), is an atypical member of the 
receptor tyrosine kinase (RTK) family. It is characterized by 
an impaired kinase activity [11] and an extracellular WNT 
inhibitory factor domain that binds WNT ligands, leading 
to the activation of β-catenin-dependent pathways [12, 13]. 
RYK controls fundamental biological processes, including 
neuronal differentiation and axon outgrowth [13, 14], and its 
deregulation has been proven to be associated with cancer: 
indeed, RYK is overexpressed in ovarian cancer tissues [15], 
is essential for WNT-5a-dependent invasiveness in glioma, 
and its expression correlates with the WHO’s histological 
grading system for glioma tissues [16].
Here, we describe a hitherto unknown function of 
RYK in establishing the stem-like phenotype of GBM 
cells. We provide evidence that the receptor plays a key 
role in conferring stemness to GBM cells by regulating 
β-catenin expression and function. RYK may therefore 
represent a new target for the treatment of GBM.
RESULTS
RYK is overexpressed in glioblastoma and stem-
like glioblastoma cells
We gathered RYK expression data on 23 normal 
brain samples and 77 GBM samples from the Gene 
Expression Omnibus (GEO) Profiles database [17] (GEO 
accession number: GDS1962). Expression of RYK mRNA 
was significantly increased in tumors compared to normal 
tissue (p-value < 0.0001) (Figure 1A), a trend confirmed 
by data obtained from the Oncomine database [18]
(Supplementary Figure 1A).
RYK mRNA expression was then analyzed in six 
patient-derived GSC lines and six patient-derived GSC 
lines induced to differentiate. As shown in Figure 1B, 
RYK was expressed at a greater extent in GSCs than in 
differentiated cells. Furthermore, we showed a decrease 
of RYK protein levels in three patient derived GSCs 
compared to their differentiated counterpart (Figure 1C), 
suggesting a possible role for RYK in the maintenance and 
promotion of CSCs. Of note, neurospheres derived from 
different continuous GBM cell lines had high levels of 
RYK mRNA (Figure 1D) and/or protein (Figure 1F) beside 
other well-established GSC markers, including NANOG, 
SOX2, OCT3/4 (Figure 1E and 1F), NESTIN, CD133, and 
EZH2 (Supplementary Figure 1B and 1C). Taken together, 
these findings indicate that RYK is strongly upregulated in 
GBM stem cells and are suggestive of a possible role of 
this receptor in the promotion of stemness.
Knockdown of RYK inhibits self-renewal in 
GSCs
We next investigated the effect of silencing RYK 
on two different patient-derived GSC lines (patients #1 
and #83) [19]. The ability of GSCs to form neurospheres 
in vitro was drastically impaired by knocking down RYK 
expression with a specific siRNA (Figure 2A); moreover, 
GSC markers were decreased (Figure 2B). To further 
confirm the role of RYK as a stemness promoter in GBM, 
we transfected siRyk or siRNA control sequences into 
three continuous GBM cell lines under either adherent 
or stem cells-enriched conditions. RYK silencing was 
evaluated by RT-PCR and western blot (supplementary 
Figure 2A and 2B). As expected, GBM cells with silenced 
expression of RYK had a significantly impaired ability to 
form neurospheres (Figure 2C). 
RYK knockdown induced a decrease of the 
expression of stem markers as assessed by RT-PCR 
(Figure 2D–2E) and/or Western blotting (Figure 2F and 
Supplementary Figure 2B). 
RYK overexpression promotes neurosphere 
formation
To move forward in the understanding of the 
oncogenic potential of RYK in GSCs and continuous 
cell lines, we performed a sphere-formation assay in 
AM38, U87MG and U251MG. We found that the 
formation of spheres was significantly enhanced when 
RYK was overexpressed in differentiated and in stem-
like cells (Figure 3A). Furthermore, transfection of 
differentiated GBM cells with h-RYK increased stemness 
markers at mRNA and protein levels (Figure 3B–3C and 
Supplementary Figure 3A). RYK overexpression was 
assessed by western blot, as shown in Supplementary 
Figure 3B. Taken together, these findings confirm that 
RYK plays a central role in neurosphere formation.
RYK enhances stem cell frequency, anchorage-
independent growth and cell migration
We next performed limiting dilution assay (LDA) 
in U87MG and U251MG cell lines under sphere-forming 
condition. Data were analyzed using ELDA (Extreme 
Limiting Dilution Analysis) software [20]. Cells transfected 
with h-RYK showed an increased spheroid frequency, 
demonstrating that RYK expression is able to enrich the 
stem-like population (Figure 4A). Conversely, RYK 
knockdown resulted in a reduced stem cells frequency 
(Figure 4B). Moreover, to explore other cancer-promoting 
effects of RYK, we investigated whether it had an impact on 
anchorage-independent cell growth and on cell migration. 
AM38 and U251MG cells forced to overexpress RYK 
had an increased capability to form colonies in a semi-
solid medium (Figure 4C, left panel); in contrast, RYK 
knockdown determined a reduction in colony formation 
(Figure 4C, right panel). Moreover, the migration of AM38 
and U87MG cell lines was increased upon overexpression 
of RYK (Figure 4D, left panel), and lost upon knockdown 
(Figure 4D, right panel). These results clearly demonstrate 
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Figure 1: RYK is overexpressed in GBMs and GSCs. (A) A significant increase in RYK expression was identified in GBM tissues 
(n = 77) compared to normal brains (n = 23). RYK expression data was obtained from the GEO Profiles database. (B) RYK’s mRNA 
expression is greater in patient-derived GSCs (n = 6) compared to patient-derived GSCs induced to differentiate (n = 6). RYK expression 
was assessed by real-time PCR and normalized against β-actin. In (C), RYK, NANOG, SOX2, and OCT3/4 protein levels were assessed by 
Western Blot in three patient-derived GSCs (#1, #83 and #169) and their differentiated counterpart. Real-time PCR (D, E) and/or Western 
blotting (F) were performed to analyze RYK, NANOG, SOX2, and OCT3/4 mRNA and/or protein levels in differentiated and stem-like 
GBM cell lines (AM38, U87MG, U251MG, A172 and LN18). In c and f, Western blots from representative experiments; β-actin was used 
as loading control. In (C) the experiments were repeated at least twice. In (A, B, D and E), statistical significance calculated using Student’s 
t-test (p < 0.05 considered significant). Results presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. In (C) the 
blots representing Ryk, Nanog, Oct3/4 and Sox2 for patient #1 are from the same gel. The blots representing Ryk and Oct3/4 for patient #83 
are from the same gel. The blots representing Ryk and Oct 3/4 and the blots representing Nanog and Sox2 for patient #169 are from the same 
gels. In (F) the blots representing Ryk and Sox2 for AM38 are from the same gel. The blots representing Ryk, Oct 3/4 and Sox2 for A172 
are from the same gel. The blots representing Ryk and Oct3/4 are from the same gel. Therefore they have the same β-actin normalization.
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Figure 2: RYK silencing affects neurosphere formation. GBM patient-derived stem-like cells (#1, #83) or GBM cell lines (AM38, 
U87MG, and U251MG) were transfected with Ryk siRNA or a control siRNA sequence. The ability to grow as neurospheres and the 
expression of stem markers was then analyzed. Knock-down of RYK expression reduced sphere number in both patients analyzed (A) as 
well as in the GBM cell lines (C). Data representative of three independent experiments. RYK knockdown also decreased the GSC markers 
NANOG, OCT3/4, and SOX2 at mRNA and protein levels (D–F). In (D) and (E) mRNA expression was assessed by real-time PCR and 
normalized against β-actin. Experiments were repeated at least twice. In (B) and (F), Western blots from representative experiments; β-actin 
was used as loading control. In (A, C, D, and F), statistical significance calculated using Student’s t-test (p < 0.05 considered significant). 
Results presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. In (B) the blots representing Nanog, Oct3/4 and 
Sox2 for patient #1 are from the same gel. The blots representing Nanog and Sox2 for patient #83 are from the same gel. Therefore they 
have the same β-actin normalization.
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Figure 3: RYK overexpression promotes neurosphere formation. Adherent GBM (U87MG and U251MG) and stem-like derived 
cells (AM38, U87MG, and U251MG) were transfected with h-RYK cDNA or a control vector. The ability to grow as neurospheres and the 
expression of stem markers were then analyzed. RYK overexpression increased sphere number in GBM cell lines (A, left panel) as well as 
in stem-like GBM cells (A, right panel). Data representative of three independent experiments. RYK knockdown also decreased the GSC 
markers NANOG, OCT3/4, and SOX2 at mRNA and protein levels in all continuous cell lines analyzed (B–C). In (B), mRNA expression 
was assessed by real-time PCR and normalized against β-actin. Experiments were repeated at least twice. In (C), Western blots are from 
representative experiments, and β-actin was used as loading control. In (A) and (B), statistical significance calculated using Student’s t-test 
(p < 0.05 considered significant). Results presented as mean ± SD. **p < 0.01; ***p < 0.001; ****p < 0.0001. In (C) the blots representing 
Oct3/4 and Nanog for AM38 are from the same gel. Therefore they have the same β-actin normalization.
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Figure 4: RYK’s effects on GBM cells. Glioblastoma cell lines (AM38, U87MG, and U251MG) were transfected with h-RYK cDNA 
or with an siRyk-RNA sequence. The in vitro LDA revealed that RYK overexpression enriched the stem-like population in U87MG and 
U251 cell lines (A). On the contrary, RYK knockdown in U87MG reduced the stem cells frequency (B). Limiting dilution analyses were 
performed using Extreme Limiting Dilution Analysis (http://bioinf.wehi.edu.au/software/elda). (C) Anchorage-independent cell growth 
was analyzed by a soft-agar assay 14 days after transfection. RYK overexpression promoted anchorage-independent cell growth (left 
panel), whereas its knockdown produced an opposite effect (right panel). Data representative of two independent experiments. (D) Cell 
migration was analyzed by a transwell migration assay. RYK overexpression increased cell migration (left panel), an effect reverted 
by silencing (right panel). Data in (C) and (D) representative of three independent experiments. Statistical significance calculated using 
Student’s t-test (p < 0.05 considered significant). Results presented as mean ± SD. *p < 0.05; **p < 0.01; ***.
Oncotarget7www.impactjournals.com/oncotarget
that, besides behaving as a stemness promoter, RYK acts as 
an oncogenic factor, enhancing anchorage-independent cell 
growth and cell migration in GBM.
β-Catenin is a key molecule of RYK-mediated 
effects
Since RYK is involved in the WNT/β-catenin 
pathway, we reasoned that its role as a stemness promoter 
in GBM may be mediated by stabilization of β-catenin. 
Indeed, expression of β-catenin mRNA and protein 
was higher in cell line-derived GSCs compared to their 
differentiated counterpart (Figure 5A, 5B). Furthermore, 
transfection of siRyk in GSCs derived from patients #1 and 
#83 and in GBM cells downregulated β-catenin expression 
(Figure 5C), whereas overexpression of RYK in GBM 
cells upregulated β-catenin (Figure 5D). Coherently, 
knock-down of β-catenin with a specific siRNA mimicked 
the effects of siRyk transfection, reducing neurosphere 
formation in patient #83-derived GSCs and in U87MG 
and U251MG cells (Figure 5E).
β-catenin overexpression rescues the RYK-
mediated stemness phenotype
To demonstrate a causal link between RYK and 
β-catenin in determining stemness, we performed a rescue 
experiment by transfecting GBM cells with siRyk together 
with β-catenin cDNA. Expression of exogenous β-catenin 
counteracted the effect of siRyk on neurosphere formation 
(Figure 6A) and increased the expression of stem-cell 
markers (Figure 6B–6D). Taken together, these findings 
strongly support the hypothesis that the role of RYK in 
promoting the stemness of GBM is mediated, at least in 
part, by the stabilization of β-catenin.
DISCUSSION
RYK is an atypical member of the RTK family 
able to function as a WNT co-receptor and activate the 
canonical β-catenin-dependent pathway. RYK has been 
previously linked to ovarian cancer and brain tumors 
[15, 16], but its role in the pathogenesis of GBM has been 
poorly investigated. Here we demonstrate for the first 
time that RYK promotes the stemness properties of GBM 
cells and is involved in GBM stem cell maintenance. 
Indeed, we found RYK dramatically upregulated in a 
large cohort of GBM samples and in GBM cancer stem 
cells either obtained directly from patients or derived from 
commercially available GBM cell lines. These results 
enforce previous observations on the oncogenic role of 
RYK in GBM [16, 21], and are indicative of a possible 
key role of the receptor in GSC maintenance.
GSCs are characterized by the ability to grow as 
neurospheres under appropriate culture conditions and 
by uncontrolled expression of one or more pluripotency-
related transcription factors, such as NANOG, OCT3/4, 
and SOX2. Minimal expression of these regulatory 
genes in normal brain cells promotes maintenance of 
quiescence and low self-renew in the NSC compartment; 
overexpression of one or more of these factors leads to a 
GSC phenotype via oncogenic activation, transformation, 
and aberrant expansion of a mutated cell pool [22]. Our 
knock-down and forced-expression studies demonstrate 
that RYK modulates neurosphere formation and the 
expression of OCT3/4, SOX2, and NANOG in GSCs 
derived from three cell lines and two patients.
Moreover, we demonstrate that when RYK 
is overexpressed in differentiated cells, it promotes 
de-differentiation and conversion toward a stemness 
phenotype. This suggests that RYK not only sustains the 
stemness features of GSCs, but also promotes a shift to 
a more undifferentiated state. Therefore, RYK may exert 
a tumorigenic role by enriching the GSCs pool or by 
initiating malignant transformation of cells. Consistent 
with this, RYK overexpression has been reported to induce 
the acquisition of tumorigenic properties in the mouse 
fibroblast cell line NIH3T3 [21].
We also observed that GBM cells are strongly 
dependent on RYK for anchorage-independent growth and 
for migration. This is in agreement with results obtained 
by Habu et al. demonstrating that RYK is required for the 
WNT-5a-dependent invasive activity of glioma cells [16], 
and suggests that RYK participates in conferring a more 
aggressive phenotype.
We hypothesized that the observed effects were 
mainly mediated through the regulation of β-catenin 
expression levels. Indeed, the WNT/β-catenin pathway 
is known to critically regulate self-renewal and 
differentiation of neural stem/progenitor cells [23, 24]; 
moreover, it is essential for glioma tumorigenesis and for 
the maintenance of an undifferentiated state in GBM cells 
[9, 25]. We found through overexpression and silencing 
experiments that the higher β-catenin level in the stem-
like cells of glioblastoma is dependent upon RYK; in 
addition, knock-down of β-catenin strongly suppressed 
the stemness phenotype of GBM cells. Finally, our rescue 
experiments demonstrate that transfection of β-catenin 
cDNA can partially recover the losses in sphere-forming 
ability and stemness-marker expression associated with 
RYK silencing.
In conclusion, we provide a novel function for 
RYK: it promotes the stemness of GBM cells, mediating 
this role through β-catenin signaling. In glioblastoma 
stem cells, RYK is overexpressed, is required for the 
activation of the pluripotency-related transcription-factor 
circuitry, and sustains neurosphere formation, leading to 
the establishment and maintenance of an undifferentiated 
state. As a consequence, blockade of RYK activation may 
represent a novel strategy for the treatment of GBM.
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Figure 5: RYK’s effects on stem phenotype are mediated by β-catenin. β-catenin mRNA and protein levels were assessed in 
differentiated and in stem-like GBM cell lines (AM38, U87MG, and U251MG) by real-time PCR (A) and Western blotting (B). Glioblastoma 
patient-derived stem-like cells (#1 and #83) and differentiated cells (derived from AM38, U87MG, and U251MG cells) were transfected 
with a RYK siRNA sequence and/or RYK cDNA. RYK knockdown decreased β-catenin in all the cell lines analyzed (C). In contrast, 
RYK overexpression improved protein level in GBM lines (D). GBM patient-derived stem-like cells (#83) and GBM cell lines (AM38 
and U251MG) were transfected with a β-catenin siRNA or a control siRNA and the ability to grow as neurospheres was then analyzed. 
β-Catenin knockdown reduced sphere number in GSCs from patient #83 and in the two GBM cell lines analyzed (E). Data representative 
of three independent experiments. In (A), mRNA expression was assessed by real-time PCR and normalized against β-actin. Experiments 
were repeated at least twice. In (B), (C), and (D), Western blots from representative experiments; β-actin was used as loading control. In 
(A) and (E), statistical significance calculated using Student’s t-test (p < 0.05 was considered significant). Results presented as mean ± SD. 
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. In (B) the blot representing β-catenin for AM38 is from the same gel of Figure 1F. 
In (C) the blot representing β-catenin for patient #83 is from the same gel of Figure 2C. The blots representing β-catenin for AM38 and 
U87MG are from the same gel of Figure 2F. In (D) the blots representing β-catenin for AM38, U87MG and U251MG are from the same 
gel of Figure 3C. Therefore they have the same β-actin normalization.
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Figure 6: β-Catenin overexpression rescues the effect of RYK knockdown on stemness. AM38 and U87MG cells were 
co-transfected with RYK siRNA or a control siRNA sequence, and with either a vector carrying β-catenin or a control sequence. Exogenous 
β-catenin expression was able to partially counteract the effects of RYK silencing on the ability to form neurospheres (A) and on stem 
marker expression (B–D). In (A), data representative of three independent experiments. In (B–D), mRNA expression was assessed by 
real-time PCR and normalized against β-actin. Experiments were repeated at least twice. Statistical significance was calculated using 
Student’s t-test (p < 0.05 considered significant). Results presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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MATERIAL AND METHODS
Cell and neurosphere cultures
The glioblastoma cell line U87MG was obtained 
from American Type Culture Collection (ATTC, LG 
Standards, Milan, Italy); AM38 and U251MG cells were 
kindly donated by Dr Frank Furnari (La Jolla University, 
CA, USA). Cells were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 
and 100 U/ml penicillin/streptomycin (all media and 
supplements were purchased from Sigma-Aldrich, Milan, 
Italy, unless otherwise stated). For neurosphere cultures, 
single cells were plated at a density of 1,000 cells/ml 
and grown in serum-free DMEM-F12 supplemented 
with B27 (ThermoFisher Scientific, Milan, Italy), 10 ng/
ml EGF, 20 ng/ml basic FGF (bFGF) (BD Biosciences, 
Milan, Italy), and antibiotic-antimycotics (ThermoFisher 
Scientific). After 5–7 days, neurospheres, which appeared 
as clusters of floating, viable cells, were collected by 
gentle centrifugation (800 rpm) and dissociated with 
0.25% trypsin for 5 min.
Glioblastoma stem-cell isolation and 
differentiation
GBM tissue specimens were obtained from 
adult patients undergoing craniotomy at the Institute of 
Neurosurgery, School of Medicine, Università Cattolica, 
Rome, Italy, as previously described  [19, 26, 27]. 
Informed consent was obtained from patients before 
surgery. Stem cells were isolated through mechanical 
dissociation of GBM tumor tissue and cultured at low 
density in a serum-free medium supplemented with 
EGF and bFGF as described elsewhere [27]. To induce 
differentiation, cells were plated on flasks coated with BD 
Matrigel™ Basement Membrane Matrix (BD Biosciences) 
in the absence of EGF and bFGF for 2 weeks. 
Cell transfection
For transient RYK overexpression, cells were 
transfected with 4 µg of pcDNA3-h-RYK or pcDNA3. 
Ryk cDNA was kindly provided by Dr Stacker [28]. 
Lipopfectamin 2000 (Invitrogen, Thermo Fisher, Milan, 
Italy) was used for U87MG and patient-derived stem 
cells; X-tremeGENE9 DNA Transfection Reagent (Roche, 
Milan, Italy) was used for U251MG and AM38 cell lines.
To transiently knockdown RYK or β-catenin cDNA, 
100nM of siRyk (Ambion, Thermo Fisher), siβ-catenin 
(Santa Cruz Biotechnology, MA, USA), or siRNA 
control (Ambion,Thermo Fisher) were transfected using 
Lipopfectamin 2000 for patient-derived stem cells or 
Oligofectamine (Invitrogen, Thermo Fisher) for all other 
cell lines.
Protein isolation and Western blotting
Cells were washed twice in ice-cold PBS and then 
lysed in JS buffer (50 mM HEPES, pH 7.5, containing 
150 mM NaCl, 1% glycerol, 1% Triton X-100, 1.5 mM 
MgCl2, 5 mM EGTA, 1 mM Na3VO4, and 1X protease 
inhibitor cocktail) as described [29]. Protein concentration 
was determined with a Bradford assay (Bio-Rad, Milan, 
Italy) using bovine serum albumin as standard; equal 
amounts of proteins were resolved on SDS-PAGE 
(10% acrylamide), electroblotted onto nitrocellulose 
membranes (G&E Healthcare, Milan, Italy), blocked 
for 1 h with 5% non-fat dry milk in Tris-buffered saline 
(TBS) containing 0.1% Tween-20, and incubated at 4°C 
overnight with primary antibody. Detection was performed 
by peroxidase-conjugated secondary antibodies (Santa 
Cruz Biotechnology) using enhanced chemiluminescence 
(EuroClone, Milan Italy). Primary antibodies were: 
anti-OCT3/4, anti-SOX2, anti-NANOG, anti-NESTIN 
(all from Santa Cruz Biotechnology), anti-EZH2, anti- 
β-catenin (from Cell Signaling Technology, EuroClone), 
anti-CD133 (Proteintech, Rosemont, IL, USA), anti-RYK 
(Genetex, CA, USA), and anti-β-actin (Sigma-Adrich).
RNA extraction and real-time PCR
Total RNA was extracted using EuroGOLDTriFast 
(EuroClone, Milan, Italy) according to the manufacturer’s 
protocol. Reverse transcription of total mRNA was 
performed as described [30] starting from equal amounts of 
total RNA/sample (500 ng) using SuperScript® III Reverse 
Transcriptase (Invitrogen, Milan, Italy). Quantitative 
analyses of RYK, NANOG, OCT3/4, SOX2, EZH2, nestin, 
CD133, β-catenin, and β-actin (as an internal reference) 
were performed by real-time PCR using specific primers 
(IDT, Bologna, Italy) and iQTM SYBR Green Supermix 
(Bio-Rad). All reactions were run in triplicate. To 
amplificate genes of interest we used the following primers: 
β-ACTIN fw:5'- TGCGTGACATTAAGGAGAAG 
-3', rv:5'-GCTCGTAGCTCTTCTCCA-3'; 
NESTIN fw:5'-CAGGAGAAACAGGGCCTACA 
-3', rv: 5'-AGCTGAGGGAAGTCTTGGAG-3'; 
EZH2 fw:5'-GAGTTGGTGAATGCCCTTGG-3', 
rv:5'-TGCTGTGCCCTTATCTGGAA-3'; 
OCT3/4 fw:5'-CGAAAGAGAAAGCGAACCAG 
-3', rv:5'-GCCGGTTACAGAACCACACT-3'; 
SOX-2 fw:5'-GCACATGAACGGCTGGAGCAAC 
G-3', rv:5'-GCTGCGAGTAGGACATGCTGTAGG-3'; 
NANOG fw:5'-CAAAGGCAAACAACCCACTT 
-3', rv:5'-TCTGGAACCAGGTCTTCACC-3';
RYK fw:5'-TGTAAGCTGCGAGGTCTTCA-3', 
rv:5'-TTGCTGAGAAATTGCCTGTG-3'; 
β-CATENIN fw:5'-TCCCACTAATGTCCAGCGTT 
-3'; rv:5'-ATGGACCATAACTGCAGCCT-3'; 
CD133 fw:5'-TTCTTGACCGACTGAGACCC-3', 
rv:5'-CCAAGCACAGAGGGTXATTG-3'.
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Neurosphere-forming assay
Cells were plated in 60mm dishes in stem cell 
medium (see above). Colonies were counted under an 
inverted microscope (Nikon, Milan, Italy) and then 
photographed, as described. 
In vitro limiting dilution assay
Cells were seeded in stem cell medium (see above) 
at 1, 5 and 10 cells per well into a 96-well plate. One week 
after seeding, the number of wells containing spheroids 
for each cell plating density was counted, and Extreme 
limiting dilution analysis was performed using software 
available at http://bioinf.wehi.edu.au/software/elda.
Soft-agar assay
Cells were plated in 60mm dishes in a solution 
containing 2xDMEM, TPB buffer, and 1.25% noble agar 
(Difco, BDBiosciences), as previously described [31]. 
Briefly, cells were harvested, counted, and a 7-ml layer of 
noble agar solution left to polymerize on the bottom of the 
dishes. Cells were resuspended in 2ml of solution, seeded, 
and left to grow for 2 weeks in the incubator.
Transwell migration assay
Dissociated tumor spheres were counted and 
1.4 × 105 cells/point were treated or transfected as 
indicated. Following 24 h, 1 × 105 cells were seeded in the 
upper chamber of transwells (Corning, Corning, NY, USA) 
in serum-free DMEM and exposed to 10% FBS to induce 
migration (0.6 ml in the lower chamber) for an additional 
24 h, as previously described [32]. Migrated cells were 
visualized by staining with 0.1% crystal violet in 25% 
methanol and photographed with Leica Application Suite. 
The percentage of migrated cells was evaluated by eluting 
crystal violet with 1% sodium dodecyl sulfate (SDS) and 
reading the absorbance at 594 nm wavelength.
Statistical analysis
Continuous variables are given as mean ± 1 standard 
deviation. For comparison of two group, Student’s 
t-test was used to determine differences between mean 
values for normal distribution. All data were analyzed 
for significance using GraphPad Prism 6 (San Diego, 
CA, USA) software, and a probability level < 0.05 was 
considered significant throughout.
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